SCHEMBL16319378

SCHEMBL16319378

COC(=O)c1cnc(Cl)c(OCc2ccccc2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.56
LMNA P02545 2/20 0.56
PPIA P62937 1/20 0.51
SMPD1 P17405 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
HDAC6 Q9UBN7 1/20 0.50
NOTUM Q6P988 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
RAB9A P51151 2/20 0.48
NPC1 O15118 1/20 0.48
LRRK2 Q5S007 2/20 0.47
MRGPRX4 Q96LA9 3/20 0.46
KMT2A Q03164 1/20 0.46
MAPT P10636 2/20 0.46
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP3A4 P08684 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14332920 0.87 PPIA (0.52) HPGDPPIASMN1; SMN2RAB9ANPC1
SCHEMBL15043883 0.86 MAOB (0.52) HPGDSMPD1HDAC1HDAC8HDAC6
SCHEMBL31132733 0.86 HPGD (0.55) HPGDSMN1; SMN2RAB9ANPC1MRGPRX4
SCHEMBL31133124 0.86 HPGD (0.55) HPGDSMN1; SMN2RAB9ANPC1MRGPRX4
SCHEMBL22502075 0.84 HPGD (0.56) HPGDLMNAPPIASMPD1HDAC1
SCHEMBL17499909 0.84 MAP4K4 (0.60) HPGDLMNAPPIASMPD1HDAC1
SCHEMBL28496944 0.83 HPGD (0.54) HPGDLMNAPPIASMPD1HDAC1
SCHEMBL31322831 0.83 MRGPRX4 (0.41) PPIASMN1; SMN2MRGPRX4KMT2AMAPT
SCHEMBL559537 0.81 NOTUM (0.58) HPGDLMNASMPD1HDAC1HDAC8
SCHEMBL2712977 0.80 MAPK1 (0.49) LMNASMN1; SMN2KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4704830-A2 MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF Septerna, Inc. (US) 2026-03-11 EP disclosed
WO-2024226914-A2 MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF SEPTERNA, INC. (US) 2024-10-31 WO disclosed
US-9181186-B2 Aromatic ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-11-10 US disclosed
US-20150045378-A1 AROMATIC RING COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-02-12 US disclosed
EP-2816032-A1 AROMATIC RING COMPOUND Takeda Pharmaceutical Company Limited (JP) 2014-12-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150045378-A1 AROMATIC RING COMPOUND GPR119, GPR27, GPR4 HPGD 3122/4885LMNA 4093/4885PPIA 4874/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.